Polyethyleneimine modification of aluminum hydroxide nanoparticle enhances antigen transportation and cross-presentation of dendritic cells

Dong, Heng; Zhang, Wen; Chen, Lin; Zhou, Na; Liu, Hui; Dong, Shiling; Hu, Hong-Ming; Mou, Yongbin

doi:10.2147/ijn.s164097

Cited by 49 publications

(21 citation statements)

References 41 publications

(39 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Changing size and surface chemistry of NPs were effective ways to regulate their effects on antigen cross-presentation intensity of DCs ( 118 , 119 ). Some metal oxide NPs such as aluminum hydroxide ( 120 ) and super-paramagnetic iron oxide NPs (SPIONs) ( 121 ) were also reported to improve the cross-presentation ability of DCs. These above studies suggested a potential strategy of using nanotechnology to develop DCs-based cancer immunotherapy.…”

Section: Nps Affect DC Functionsmentioning

confidence: 99%

Interactions Between Nanoparticles and Dendritic Cells: From the Perspective of Cancer Immunotherapy

et al. 2018

View full text Add to dashboard Cite

Dendritic cells (DCs) are the primary antigen-presenting cells and play key roles in the orchestration of the innate and adaptive immune system. Targeting DCs by nanotechnology stands as a promising strategy for cancer immunotherapy. The physicochemical properties of nanoparticles (NPs) influence their interactions with DCs, thus altering the immune outcome of DCs by changing their functions in the processes of maturation, homing, antigen processing and antigen presentation. In this review, we summarize the recent progress in targeting DCs using NPs as a drug delivery carrier in cancer immunotherapy, the recognition of NPs by DCs, and the ways the physicochemical properties of NPs affect DCs' functions. Finally, the molecular pathways in DCs that are affected by NPs are also discussed.

show abstract

Section: Nps Affect DC Functionsmentioning

confidence: 99%

Interactions Between Nanoparticles and Dendritic Cells: From the Perspective of Cancer Immunotherapy

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Coating materials play critical roles in the stabilization and subsequent functionalization of aqueous SPIO suspensions [15]. In previous studies, positively charged SPIO were shown to facilitate the cross-presentation ability of DCs to enhance the immune response, and they surpassed the effect of their oppositely charged counterparts [16, 17]. The mechanism through which differently charged SPIO can affect the antigen cross-presentation of DCs has not been clarified.…”

Section: Introductionmentioning

confidence: 99%

SPIO Enhance the Cross-Presentation and Migration of DCs and Anionic SPIO Influence the Nanoadjuvant Effects Related to Interleukin-1β

et al. 2018

Self Cite

View full text Add to dashboard Cite

Superparamagnetic iron oxide nanoparticles (SPIO) have been synthesized and explored for use as carriers of various nanoadjuvants via loading into dendritic cells (DCs). In our study, homogeneous and superparamagnetic nanoparticles are susceptible to internalization by DCs and SPIO-pulsed DCs showed excellent biocompatibility and capacity for ovalbumin (OVA) cross-presentation. Herein, we found that SPIO-loaded DCs can promote the maturation and migration of DCs in vitro. SPIO coated with 3-aminopropyltrimethoxysilane (APTS) and meso-2,3-dimercaptosuccinic acid (DMSA), which present positive and negative charges, respectively, were prepared. We aimed to investigate whether the surface charge of SPIO can affect the antigen cross-presentation of the DCs. Additionally, the formation of interleukin-1β (IL-1β) was examined after treatment with oppositely charged SPIO to identify the nanoadjuvants mechanism. In conclusion, our results suggest that SPIO are biocompatible and can induce the migration of DCs into secondary lymph nodes. SPIO coated with APTS (SPIO/A+) exhibited excellent adjuvant potentials for the promotion of antigen cross-presentation and T cell activation and surpassed that of DMSA-coated nanoparticles (SPIO/D−). This process may be related to the secretion of IL-1β. Our study provides insights into the predictive modification of nanoadjuvants, which will be valuable in DC vaccine design and could lead to the creation of new adjuvants for applications in vaccines for humans.

show abstract

“…31,32 TAAs expressed on cancer cells are the targets for the immune system, it can be processed and presented by professional antigen-presenting cells (pAPCs) such as DCs, and then trigger antigen-specific T cell immune responses to kill tumor cells. 22,33,34 Inactivated whole tumor cells or tumor cell lysates were kept as a source of TAAs in many therapeutic vaccines due to their numerous TAAs contained. This rich source of antigens contains multiple T-cell epitopes, which could elicit a stronger overall anti-tumor response.…”

Section: Discussionmentioning

confidence: 99%

<p>Anti-Tumor Efficacy of an Adjuvant Built-In Nanovaccine Based on Ubiquitinated Proteins from Tumor Cells</p>

Huang¹,

Zhao²,

Wei³

et al. 2020

IJN

View full text Add to dashboard Cite

Background and Aim: We have previously identified ubiquitinated proteins (UPs) from tumor cell lysates as a promising vaccine for cancer immunotherapy in different mouse tumor models. In this study, we aimed at developing a highly efficient therapeutic adjuvant built-in nanovaccine (α-Al 2 O 3-UPs) by a simple method, in which UPs from tumor cells could be efficiently and conveniently enriched by α-Al 2 O 3 nanoparticles covalently coupled with Vx3 proteins (α-Al 2 O 3-CONH-Vx3). Methods: The α-Al 2 O 3 nanoparticles were modified with 4-hydroxybenzoic acid followed by coupling with ubiquitin-binding protein Vx3. It was then used to enrich UPs from 4T1 cell lysate. The stability and the efficiency for the UPs enrichment of α-Al 2 O 3-CONH-Vx3 were examined. The ability of α-Al 2 O 3-UPs to activate DCs was examined in vitro subsequently. The splenocytes from the vaccinated mice were re-stimulated with inactivated tumor cells, and the IFN-γ secretion was detected by ELISA and flow cytometry. Moreover, the therapeutic efficacy of α-Al 2 O 3-UPs, alone and in combination with chemotherapy, was examined in 4T1 tumor-bearing mice. Results: Our results showed that α-Al 2 O 3-UPs were successfully synthesized and abundant UPs from tumor cell lysate were enriched by the new method. In vitro study showed that compared to the physical mixture of α-Al 2 O 3 nanoparticles and UPs (α-Al 2 O 3 +UPs), α-Al 2 O 3-UPs stimulation resulted in higher upregulations of CD80, CD86, MHC class I, and MHC class II on DCs, indicating the higher ability of DC activation. Moreover, α-Al 2 O 3-UPs elicited a more effective immune response in mice, demonstrated by higher IFN-γ secretion than α-Al 2 O 3 +UPs. Furthermore, α-Al 2 O 3-UPs also exhibited a more potent effect on tumor growth inhibition and survival prolongation in 4T1 tumor-bearing mice. Notably, when in combination with low dose chemotherapy, the anti-tumor effect was further enhanced, rather than using α-Al 2 O 3-UPs alone. Conclusion: This study presents an adjuvant built-in nanovaccine generated by a new simple method that can be potentially applied to cancer immunotherapy and lays the experimental foundation for future clinical application.

show abstract

Polyethyleneimine modification of aluminum hydroxide nanoparticle enhances antigen transportation and cross-presentation of dendritic cells

Cited by 49 publications

References 41 publications

Interactions Between Nanoparticles and Dendritic Cells: From the Perspective of Cancer Immunotherapy

Interactions Between Nanoparticles and Dendritic Cells: From the Perspective of Cancer Immunotherapy

SPIO Enhance the Cross-Presentation and Migration of DCs and Anionic SPIO Influence the Nanoadjuvant Effects Related to Interleukin-1β

<p>Anti-Tumor Efficacy of an Adjuvant Built-In Nanovaccine Based on Ubiquitinated Proteins from Tumor Cells</p>

Contact Info

Product

Resources

About